Proactive Investors - Run By Investors For Investors

Proactive CEO Sessions next month feature bio-pharma and exploration companies

The Sydney CEO Session is on Monday, May 13, and the Melbourne session is Tuesday, May 14.
CEO Session in Sydney
Register now for the May investor events in Sydney and Melbourne

Proactive’s CEO Sessions next month feature three pharma & biotech companies developing potentially life-changing medical treatments and two exploration companies with projects that have game-changing potential.

Zelda Therapeutics Ltd (ASX:ZLD), Invitrocue Ltd (ASX:IVQ) and Oventus Medical Ltd (ASX:OVN) are the bio-pharma companies that will present to investors on May 13 and May 14.

These CEO Sessions will also feature Mongolian-focused copper-gold explorer Xanadu Mines Ltd (ASX:XAM) and Infinity Lithium Ltd (ASX:INF), which is focused on lithium in Spain.

All five companies will present at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.

READ: Zelda Therapeutics in deal with Ilera to access US market

Zelda is making significant progress in its business growth strategy with a focus on developing drugs to support clinical decision making for individual patients.

Recent developments include a heads of agreement (HoA) with medicinal cannabis company Ilera Healthcare to explore collaborative opportunities and being granted a new patent covering a novel method to predict patient disease-free survival.

The range of commercialisation opportunities with US-based Ilera include licensing of Zelda products, co-development and data sharing.

READ: Zelda Therapeutics secures patent to detect breast cancer

Zelda’s Australian patent details a method for detecting levels of expression of a novel receptor complex containing proteins HER2 and CB2.

HER2 is a recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.

READ: Invitrocue signs agreement to develop new breast cancer models for its Onco-PDO test

Invitrocue is a leading healthcare bio-analytic solutions provider that recently signed an agreement with the Shanghai Institute of Biochemistry and Cell Biology for the development of new breast cancer models for its proprietary Onco-PDO test.

The Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients.

Oventus is a medical device company commercialising a unique treatment platform for the treatment of sleep apnea and snoring.

READ: Oventus Medical launches lightweight sleep apnea treatment device in Australia

Early this year the company recently launched a lightweight sleep apnea treatment appliance in Australia, the nylon-made O2Vent Optima device.

This is a customised 3D-printed nylon oral appliance that advances the jaw forward to open the airway and improves the effectiveness of oral appliance therapy.

Optima incorporates Brisbane-based Oventus’ proprietary airway technology and is compatible with the Oventus ExVent valve technology which will also be launched this year.

READ: Xanadu Mines scoping study confirms potential of Kharmagtai Copper-Gold Project in Mongolia

Xanadu Mines recently completed an open pit scoping study at the Kharmagtai Copper-Gold Project in Mongolia, which is in the same region as Rio Tinto plc’s (LON:RIO) massive Oyu Tolgoi Copper-Gold Project.

This study confirmed the viability of near-surface copper and gold mineralisation as well as the company’s strategy to explore for high-value large copper porphyry systems in the area.

It has identified opportunities for further upside from extending the life of the planned open pit mine, assessing higher-grade underground options and evaluating oxide gold potential near-surface at several locations.

Metallurgical test work is in progress to refine the recoveries of copper and gold reporting to concentrate.

Infinity Lithium is seeking to develop its 75%-owned San Jose Lithium Project in Spain and produce battery-grade lithium hydroxide.

READ: Infinity Lithium updated PFS test work positive, remains on track

The company is on-track to complete an updated pre-feasibility study (PFS) for the project in June or July this year.

Stage I test work has been completed focusing on metallurgical test work designed to confirm previous upgrade factors from the November 2018 scoping study, which valued the project at up to US$1.017 billion.

As a result of this work, suitable amounts of concentrate have been produced for stage II hydrometallurgical test work.

This is designed to develop the sulphate-roast-water-leach (SRWL) flowsheet to a PFS standard.

After stage II, the leach solution produced will move to stage III, the final stage, where through a process of purification and crystallisation lithium hydroxide will be produced.

Register for the CEO Sessions today

Sydney details, Monday, May 13, 2019

Melbourne details, Tuesday, May 14, 2019

Featuring at both sessions will be Xanadu Mines Ltd (ASX:XAM), Infinity Lithium Ltd (ASX:INF), Zelda Therapeutics Ltd (ASX:ZLD), Invitrocue Ltd (ASX:IVQ) and Oventus Medical Ltd (ASX:OVN).

View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

Bloomsbury Publishing
March 19 2019
Peel Hunt expects “superior returns" from the firm’s investment in digital capacity
pills
March 22 2019
The healthcare-focused advisory group boasts good levels of forward bookings thanks to several new business wins at the beginning of 2019
Live Company
March 05 2019
Since listing on AIM in December 2017, the company has been pursuing an aggressive strategy of expansion and brand building that has paid off for the share price.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use